OsteoarthritisPhase 2NCT01321281
A Study to Determine if Aquamin Modulates Inflammatory Biomarkers in the Blood of Osteoarthritis and Healthy Subjects
A Phase 2 study testing AquaCal and AquaPT in people with Osteoarthritis, run by Andrea Doolan at 1 site in Ireland.
Trial summary
Osteoarthritis (OA) is the most common kind of arthritis and primarily affects the large, weight bearing joints (including the knees, lower back, hips, neck and the feet) and the joints in the hands. OA results from the breakdown of cartilage in joints, leading to joint pain and damage. Read more about this study
- Who is it for?
- Ages 18 to 65 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Osteoarthritis
- What is being tested?
- AquaCal and AquaPT
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 36 participants
- Where
- 1 siteIreland
- Study dates
- Mar 2011to May 2012
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- To be considered eligible for enrollment into the study, subjects must;
- Be able to give written informed consent.
- Be female and between 18 and 65 years of age.
- Be a non-pregnant female.
- Be in generally good health as determined by the investigator.
- Osteoarthritis patients must have a clinical diagnosis of moderate to severe osteoarthritis.
Who cannot join
- Subjects will be excluded from the study if they meet any of the below criteria;
- Are less than 18 and greater than 65 years of age.
- Are pregnant females.
- Are currently taking probiotics or vitamin supplements, or have taken them in the past 14 days.
- Have a significant acute or chronic coexisting illness (cardiovascular, gastrointestinal, endocrinological, immunological, metabolic or any condition which contraindicates, in the investigators judgment, entry to the study).
- Having a condition or taking a medication that the investigator believes would interfere with the objectives of the study, pose a safety risk or confound the interpretation of the study results; to include non-steroidal anti-inflammatory drugs (NSAIDs), steroids and vitamin.
Show all 10Show fewer
- Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the trial.
- Subjects may not be receiving treatment involving experimental drugs.
- If the subject has been in a recent experimental trial, these must have been completed not less than 30 days prior to this study.
- Have a malignant disease or any concomitant end-stage organ disease.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Randomised, Placebo Controlled Study to Determine if Aquamin (as AquaCal and AquaPT) Modulates Inflammatory Biomarkers in the Blood of Osteoarthritis and Healthy Subjects
Osteoarthritis (OA) is the most common kind of arthritis and primarily affects the large, weight bearing joints (including the knees, lower back, hips, neck and the feet) and the joints in the hands. OA results from the breakdown of cartilage in joints, leading to joint pain and damage. It affects about 8 million people in the United Kingdom and nearly 27 million people in the United States, most of whom are over the age of 45.
This study aim to determine if Aquamin (as AquaCal and AquaPT) affects molecules of inflammation in the blood of osteoarthritis and healthy subjects.
Read the detailed description
Aquamin is a seaweed-derived mineral source, which is rich in calcium, magnesium and 74 other trace minerals including zinc, iron and selenium. It is produced from the red algae, Lithothamnion Calcareum, which is found in just three locations in the world, including the south-west coast of Ireland and Iceland. During a five-year life span, these algae absorb essential minerals from the sea - this gives Aquamin its unique multimineral content. The algae then break down naturally and settle on the sea bed. These calcified skeletal remains are harvested, washed, dried and milled and provided in a capsule formulation. AquaCal is the capsule form of Aquamin. AquaPT contains green tea and pine bark extract.
Osteoarthritis (OA) is the most common kind of arthritis. OA is called degenerative arthritis, is a disease that results from the breakdown of cartilage in joints, leading to joint pain and damage. OA is very variable and there are lots of different types affecting different joints. This degenerative disease primarily affects the large, weight bearing joints (including the knees, lower back, hips, neck and the feet) and the joints in the hands. In OA, the disease begins with the degeneration of the cushion of cartilage between the joints. As it degrades, the synovium and the ends of the bones thicken, resulting in the pain and stiffness associated with arthritis. The progressive cartilage deterioration is followed by "hardening of the joints" due to calcification and bone spur formation. Treatment generally involves a combination of exercise, lifestyle modification and analgesics. If pain becomes debilitating joint replacement surgery may be used to improve the quality of life.
Symptoms of Osteoarthritis include early morning joint stiffness and pain, loss or restriction of joint mobility, pain that is worse after use, stiffness after periods of rest, creaking/cracking of joints after movement (also known as crepitus), tenderness and swelling in certain areas, restricted mobility, pain in the joint before or during changes in the weather and deformity of the joints.
Osteoarthritis is the leading cause of chronic disability in the United States.[1] It affects about 8 million people in the United Kingdom and nearly 27 million people in the United States, most of whom are over the age of 45. A number of studies have shown that there is a greater prevalence of the disease between siblings and especially identical twins, indicating a hereditary basis [2]. Up to 60% of OA cases are thought to result from genetic factors. Other factors causing OA are congenital disorders of joints, diabetes, inflammatory diseases and all chronic forms of arthritis. In addition, injury to joints as a result of an accident, septic arthritis, Marfan syndrome, obesity, ligamentous deterioration or instability may also be factors.
Current anti-inflammatory treatments for OA while providing some relief from symptoms are suboptimal and the side effects associated with these treatments; in particular the COX-2 specific NSAID's are becoming increasingly recognized [3,4]. As a result of this, use of alternative treatments and complementary medicines are gaining popularity among OA sufferers.
In a previous study, where osteoarthritis subjects were treated with Aquamin, there was a significant improvement in the WOMAC scores for pain, stiffness, activity and composite scores over the course of the 12-week treatment, in comparison to subjects in the Placebo group[5].
Aquamin is composed of multiple minerals and the 'active ingredient' for the complex is difficult to determine. A number of the minerals in Aquamin may have anti-inflammatory and anti-oxidant properties which might directly and/or indirectly influence the efficacy of this unique complex [7,8,9]. While the prominent mineral present in Aquamin is calcium (dosage = 80% Ca U.S RDA), its role in joint health is unclear. Magnesium however, was given at the daily dosage providing 14% (male) to 18% (female) U.S. RDA [6] and over the course of this study, this increased consumption of magnesium may have influenced OA symptoms by affecting the utilization of calcium or by potentially reducing inflammation around the affected joint. Both manganese and selenium were given at the daily dosage providing up to 16% and 4% of their RDA respectfully. Both of these trace minerals have been reported to reduce the appearance of osteoarthritic lesions and reduce the severity of symptoms in OA [8,9].
- Conditions
- Osteoarthritis
- Being tested
- AquaCal, AquaPT
- Keywords
- Osteoarthritis
- Medical subject headings
- Osteoarthritis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AquaCalDietary supplement
AquaCal and AquaPT are produced by Marigot Ltd according to EU and FDA requirements.
The daily dose of 4 capsules of AquaCal provide 800mg calcium, (the EU RDA for calcium) and 74 mgs Magnesium (EU RDA 375mg).
AquaPTDietary supplement
AquaCal and AquaPT are produced by Marigot Ltd according to EU and FDA requirements.
The daily dose of 4 capsules of AquaPT provides 720mg calcium, 200mgs green tea (polyphenols) and 50 mgs pine bark extract.
| Study group | Role | What they receive |
|---|---|---|
| AquaCal | Experimental | Osteoarthritis and healthy volunteers Receives: Dietary Supplement: AquaCal |
| AquaPT | Active comparator | Osteoarthritis Receives: Dietary Supplement: AquaPT |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cytokines
Plasma cytokine concentrations (including TNFα, IL-β, NFκB, COX2 \& IL-6)
Measured: Baseline (wk 0) & wk 6
Secondary outcomes (3)
WOMAC Questionnaire
Western Ontario and McMaster Universities Arthritis Index
Measured: Wk0 & Wk6
Full Blood Count
Haemaglobin, white cell count, platelet count, haematocrit, differential white count
Measured: Wk0 & Wk6
Chemistry Profile
Including Sodium, Potassium, Chloride, Urea, Creatinine, Protein, Albumin
Measured: Wk0 & Wk6
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Mar 2011 (estimated)
- Study startMar 2011
- Primary completionMay 2012
- Study completionMay 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for OsteoarthritisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 36 participants (actual)
Sponsor and investigators
- Lead sponsor
- Andrea Doolan
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Andrea Doolan, University College Cork
- Investigators
- Timothy Dinan, Principal investigator, University College Cork
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01321281
- Sponsor's protocol ID
- APC026-Marigot
- Status last verified
- May 2012
- First submitted
- 22 Mar 2011
- Last updated
- 15 May 2012
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 15 May 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomised, Placebo Controlled Study to Determine if Aquamin (as AquaCal and AquaPT) Modulates Inflammatory Biomarkers in the Blood of Osteoarthritis and Healthy Subjects
- ClinicalTrials.gov ID
- NCT01321281
- Acronym / sponsor ID
- APC026-Marigot
- Conditions
- Osteoarthritis
- Keywords
- Osteoarthritis
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 36 participants (actual)
- Lead sponsor
- Andrea DoolanUniversity, hospital or other
- Study start
- Mar 2011
- Primary completion
- May 2012 (actual)
- Study completion
- May 2012 (actual)
- First posted
- 23 Mar 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Osteoarthritis (OA) is the most common kind of arthritis and primarily affects the large, weight bearing joints (including the knees, lower back, hips, neck and the feet) and the joints in the hands. OA results from the breakdown of cartilage in joints, leading to joint pain and damage. It affects about 8 million people in the United Kingdom and nearly 27 million people in the United States, most of whom are over the age of 45.
This study aim to determine if Aquamin (as AquaCal and AquaPT) affects molecules of inflammation in the blood of osteoarthritis and healthy subjects.
Detailed description
Aquamin is a seaweed-derived mineral source, which is rich in calcium, magnesium and 74 other trace minerals including zinc, iron and selenium. It is produced from the red algae, Lithothamnion Calcareum, which is found in just three locations in the world, including the south-west coast of Ireland and Iceland. During a five-year life span, these algae absorb essential minerals from the sea - this gives Aquamin its unique multimineral content. The algae then break down naturally and settle on the sea bed. These calcified skeletal remains are harvested, washed, dried and milled and provided in a capsule formulation. AquaCal is the capsule form of Aquamin. AquaPT contains green tea and pine bark extract.
Osteoarthritis (OA) is the most common kind of arthritis. OA is called degenerative arthritis, is a disease that results from the breakdown of cartilage in joints, leading to joint pain and damage. OA is very variable and there are lots of different types affecting different joints. This degenerative disease primarily affects the large, weight bearing joints (including the knees, lower back, hips, neck and the feet) and the joints in the hands. In OA, the disease begins with the degeneration of the cushion of cartilage between the joints. As it degrades, the synovium and the ends of the bones thicken, resulting in the pain and stiffness associated with arthritis. The progressive cartilage deterioration is followed by "hardening of the joints" due to calcification and bone spur formation. Treatment generally involves a combination of exercise, lifestyle modification and analgesics. If pain becomes debilitating joint replacement surgery may be used to improve the quality of life.
Symptoms of Osteoarthritis include early morning joint stiffness and pain, loss or restriction of joint mobility, pain that is worse after use, stiffness after periods of rest, creaking/cracking of joints after movement (also known as crepitus), tenderness and swelling in certain areas, restricted mobility, pain in the joint before or during changes in the weather and deformity of the joints.
Osteoarthritis is the leading cause of chronic disability in the United States.[1] It affects about 8 million people in the United Kingdom and nearly 27 million people in the United States, most of whom are over the age of 45. A number of studies have shown that there is a greater prevalence of the disease between siblings and especially identical twins, indicating a hereditary basis [2]. Up to 60% of OA cases are thought to result from genetic factors. Other factors causing OA are congenital disorders of joints, diabetes, inflammatory diseases and all chronic forms of arthritis. In addition, injury to joints as a result of an accident, septic arthritis, Marfan syndrome, obesity, ligamentous deterioration or instability may also be factors.
Current anti-inflammatory treatments for OA while providing some relief from symptoms are suboptimal and the side effects associated with these treatments; in particular the COX-2 specific NSAID's are becoming increasingly recognized [3,4]. As a result of this, use of alternative treatments and complementary medicines are gaining popularity among OA sufferers.
In a previous study, where osteoarthritis subjects were treated with Aquamin, there was a significant improvement in the WOMAC scores for pain, stiffness, activity and composite scores over the course of the 12-week treatment, in comparison to subjects in the Placebo group[5].
Aquamin is composed of multiple minerals and the 'active ingredient' for the complex is difficult to determine. A number of the minerals in Aquamin may have anti-inflammatory and anti-oxidant properties which might directly and/or indirectly influence the efficacy of this unique complex [7,8,9]. While the prominent mineral present in Aquamin is calcium (dosage = 80% Ca U.S RDA), its role in joint health is unclear. Magnesium however, was given at the daily dosage providing 14% (male) to 18% (female) U.S. RDA [6] and over the course of this study, this increased consumption of magnesium may have influenced OA symptoms by affecting the utilization of calcium or by potentially reducing inflammation around the affected joint. Both manganese and selenium were given at the daily dosage providing up to 16% and 4% of their RDA respectfully. Both of these trace minerals have been reported to reduce the appearance of osteoarthritic lesions and reduce the severity of symptoms in OA [8,9].
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, care provider)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| AquaCal | Experimental | Dietary Supplement: AquaCalOsteoarthritis and healthy volunteers |
| AquaPT | Active comparator | Dietary Supplement: AquaPTOsteoarthritis |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- To be considered eligible for enrollment into the study, subjects must;
- Be able to give written informed consent.
- Be female and between 18 and 65 years of age.
- Be a non-pregnant female.
- Be in generally good health as determined by the investigator.
Key exclusion criteria (10 listed)
- Subjects will be excluded from the study if they meet any of the below criteria;
- Are less than 18 and greater than 65 years of age.
- Are pregnant females.
- Are currently taking probiotics or vitamin supplements, or have taken them in the past 14 days.
- Have a significant acute or chronic coexisting illness (cardiovascular, gastrointestinal, endocrinological, immunological, metabolic or any condition which contraindicates, in the investigators judgment, entry to the study).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AquaCalAquaCal and AquaPT are produced by Marigot Ltd according to EU and FDA requirements. The daily dose of 4 capsules of AquaCal provide 800mg calcium, (the EU RDA for calcium) and 74 mgs Magnesium (EU RDA 375mg). | Dietary supplement | AquaCal |
| AquaPTAquaCal and AquaPT are produced by Marigot Ltd according to EU and FDA requirements. The daily dose of 4 capsules of AquaPT provides 720mg calcium, 200mgs green tea (polyphenols) and 50 mgs pine bark extract. | Dietary supplement | AquaPT |
Primary outcome
Cytokines
Time frame: Baseline (wk 0) & wk 6
Plasma cytokine concentrations (including TNFα, IL-β, NFκB, COX2 \& IL-6)
3 secondary outcomes
WOMAC Questionnaire
Time frame: Wk0 & Wk6
Full Blood Count
Time frame: Wk0 & Wk6
Chemistry Profile
Time frame: Wk0 & Wk6
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 May 2012.
Related trials for Osteoarthritis
Not yet recruiting
Holistic Healing for Knee Osteoarthritis
Knee Osteoarthritis (Knee OA)
Active, not recruiting
Effectiveness of Therapeutic Exercises on Spinopelvic Mobility
Osteoarthritis (OA) of the Hip
Recruiting
Effect of Anti-inflammatory Diet in Osteoarthritis
Osteoarthritis, Knee
Active, not recruitingPhase 2/3
Single vs Triple Hyaluronic Acid in Knee Osteoarthritis
Osteoarthritis, Knee
Not yet recruiting
The Feasibility of a Virtual/Home-based OA Treatment Program in Older Adults With OA and Multimorbidity
Osteoarthritis of the Knee
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Timothy Dinan principal investigator
University College Cork
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing AquaCal and AquaPT in people with Osteoarthritis, run by Andrea Doolan at 1 site in Ireland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 May 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Ireland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cytokines (time frame: Baseline (wk 0) & wk 6). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2012.